Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.81 USD
Change Today +0.04 / 1.06%
Volume 630.4K
ONVO On Other Exchanges
Symbol
Exchange
Frankfurt
As of 11:48 AM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

organovo holdings inc (ONVO) Snapshot

Open
$3.83
Previous Close
$3.77
Day High
$3.95
Day Low
$3.78
52 Week High
07/7/14 - $9.25
52 Week Low
03/30/15 - $3.29
Market Cap
346.6M
Average Volume 10 Days
3.3M
EPS TTM
$-0.38
Shares Outstanding
91.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ORGANOVO HOLDINGS INC (ONVO)

organovo holdings inc (ONVO) Related Bloomberg News

View More Bloomberg News

organovo holdings inc (ONVO) Related Businessweek News

View More BusinessWeek News

organovo holdings inc (ONVO) Details

Organovo Holdings, Inc., an early commercial stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. It is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair, and functional tissue patches for the repair or replacement of damaged tissues and organs. The company has a collaboration agreement with Merck Sharp & Dohme Corp. (Merck). that provides Merck access to the company’s commercial exVive3D human liver tissue service, as well as to develop multiple custom tissue models. Organovo Holdings, Inc. was founded in 2007 and is based in San Diego, California.

80 Employees
Last Reported Date: 06/9/15
Founded in 2007

organovo holdings inc (ONVO) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $362.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $289.1K
Chief Strategy Officer
Total Annual Compensation: $289.8K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $289.1K
Executive Vice President of Commercial Operat...
Total Annual Compensation: $268.5K
Compensation as of Fiscal Year 2014.

organovo holdings inc (ONVO) Key Developments

Organovo Holdings Seeks Acquisitions

Organovo Holdings, Inc. (AMEX:ONVO) is seeking acquisitions. Organovo has filed a follow-on equity offering, the net proceeds of which will be used for general corporate purposes, including research and development, the development and commercialization of its products, general administrative expenses, license or technology acquisitions, and working capital and capital expenditures.

Organovo Holdings, Inc. Presents at BIO International Convention 2015, Jun-18-2015 02:00 PM

Organovo Holdings, Inc. Presents at BIO International Convention 2015, Jun-18-2015 02:00 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Sharon Collins Presnell, Chief Technology Officer and Executive Vice President of Research & Development.

Organovo Holdings, Inc. Reports Consolidated Unaudited Earnings Results for the Year Ended March 31, 2015

Organovo Holdings, Inc. reported consolidated unaudited earnings results for the year ended March 31, 2015. For the quarter, the company reported total revenues of $571,000 compared with $379,000 for the same period last year. Loss from operations was $30,297,000 compared with $20,649,000 for the same period last year. Net loss was $30,082,000 or $0.38 basic and diluted per share compared with $25,848,000 or $0.35 basic and diluted per share for the same period last year. Net cash used in operating activities was $19,601,000 compared with $15,561,000 for the same period last year. Purchases of fixed assets were $1,517,000 compared with $277,000 for the same period last year. Revenues increase reflects the recognition of $0.3 million in commercial revenue since the company's product launch in November 2014, partially offset by a $0.1 million decrease in collaboration revenue due to the completion of one of the Company's larger collaborative research agreements during the year ended March 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONVO:US $3.81 USD +0.04

ONVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $3.62 USD -0.01
Cytori Therapeutics Inc $0.57 USD +0.013
Fibrocell Science Inc $5.14 USD -0.13
Ocata Therapeutics Inc $5.28 USD +0.01
Osiris Therapeutics Inc $19.55 USD +0.09
View Industry Companies
 

Industry Analysis

ONVO

Industry Average

Valuation ONVO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 517.3x
Price/Book 6.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 502.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORGANOVO HOLDINGS INC, please visit www.organovo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.